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Diastereodivergent synthesis of chiral tetrahydropyrrolodiazepinediones via a one-pot 
intramolecular aza-Michael/lactamization sequence 
Spandan Chennamadhavuni,§ James S. Panek, John A. Porco, Jr, and Lauren E. Brown* 
Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, 590 
Commonwealth Avenue, Boston, Massachusetts 02215. 
ABSTRACT 
A modular and diastereodivergent synthesis of tetrahydro-1H-pyrrolo[1,2d]diazepin(2,5)-diones is 
presented. The tetrahydropyrrolodiazepindione scaffold is obtained via a base-mediated three-step 
isomerization/tandem cyclization of amino acid-coupled homoallylic amino esters. Diastereoselectivity of 
the process is mediated by the interplay of a kinetic cyclization event and a propensity for thermodynamic 
epimerization at two labile chiral centers, giving rise to two distinct major diastereomers dependent on 
starting material stereochemistry and reaction conditions selected. Herein, we present a synthetic and 
computational study for this tandem process on a variety of amino ester substrates. 
 
INTRODUCTION 
Diversity-oriented synthesis relies on the rapid and efficient assembly of unique three-dimensional 
molecular scaffolds from modular, stereochemically well-defined building blocks.1 Such building blocks 
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may be obtained from asymmetric synthetic methodologies as well as nature’s “chiral pool.” We have 
previously reported studies employing chiral homoallylic amino- and hydroxy-esters, obtained via 
asymmetric crotylation of aldehydes and imines, as reliable synthons for the assembly of diverse 
polyketide-like molecular libraries.2-3 In the course of a reaction screening campaign targeting challenging 
intramolecular lactamization of amino-acid-coupled homoallylic amine 1 to form 2, we have discovered a 
highly diastereoselective and diastereodivergent one-pot, three-step intramolecular cyclization sequence 
that gives rise to tetrahydro-1H-pyrrolo[1,2-d][1,4]diazepeine-(2,5)-diones of type 3 (Scheme 1). In the 
literature, examples of synthetic tetrahydropyrrolo[1,2-d][1,4]diazepinones are limited in scope, with 
isolated reports from Paquette and Scott in 1968,4 Lavagnino and Ryan in 1983,5 and Guryn in 1985.6 
Fobian and Moeller have also reported the synthesis of chiral bicyclic piperazinones via intramolecular, 
reductive amination of aldehyde-tethered substrates derived from proline-derived dipeptides.7 More 
recently, Sheng and coworkers described the unexpected production of tetrahydropyrrolodiazepinones 
through acid-induced rearrangement of pyrrolo-oxazocines.8 Lubell and coworkers have developed a three-
step synthesis of pyrrolodiazapinones from α-aminoacyl-β-amino esters,9 and in 2015 demonstrated the 
utility of these compounds, which possess dihedral ϕ/ψ angles reminiscent of an ideal inverse γ-turn,10-11 as 
peptidomimetic modulators of vasoconstriction.12 Given that the peptidomimetic 
tetrahydropyrrolodiazepinone scaffold is an underutilized heterocycle in the context of diversity-oriented 
library synthesis, we have sought to further explore efficient and sterochemically well-defined tandem 
reactions to access these compounds. 
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Scheme 1. Reaction screen targeting macrolactam 2 from amino acid-coupled homoallylic amines 1 produced 
pyrrolodiazepines 3 under basic conditions. 
 
RESULTS AND DISCUSSION 
Initial reaction screening efforts to obtain macrolactam 2 focused on conditions known to effect 
transamidations or transesterifications13 including zirconium (IV) catalysis with hydroxypyridine,14-15 tin-
mediated transesterifications,16 and treatment with anionic acyl transfer catalysts17 produced in situ by 
reaction of various heterocycles with DBU. While none of the screened conditions produced the desired 
10-membered macrocycle 2, we identified a subset of DBU/triazole acyl transfer reaction conditions that 
produced a new product. NMR analysis suggested the bicyclic structure (S,S)-3a, which was later confirmed 
by X-ray crystallography (Figure 1A). Notably, and similar to Lubell’s pyrrolodiazepinones, 
tetrahydropyrrolodiazepindione (S,S)-3a contains peptidic dihedral angles (ϕ = -74° and ψ = 73°) within 
range of an ideal inverse γ-turn (ϕ -70° to -85°, ψ 60° to 70°, Figure 1B).10-11  
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Figure 1. (A) X-ray crystal structure of (S,S)-3a, with atomic displacement ellipsoids represented at the 50% 
contour probability level. (B) ϕ/ψ angles measured from the X-ray structure. 
Preliminary optimization studies utilizing UPLC/MS for analysis indicated the greatest conversion of 1a 
(initially used as the HCl salt) to 3a occurred on treatment with two equivalents of DBU in CH3CN with 
microwave heating (145 °C, 45 minutes). Using these conditions, product 3a was isolated in 2.7:1 crude 
d.r., and was then chromatographically purified to a single diastereomer in 63% yield (Scheme 2). The 
minor diastereomer observed in the crude, later identified to be (R,R)-3a (vide infra), was not isolated. 
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Scheme 2.  Reaction conditions producing (S,S)-3a. 
 
In order to evaluate the scope of this transformation, a small series of substrates was synthesized 
with variation of both homoallylic amine and amino acid building blocks (Scheme 3). Alloc-protected 
homoallylic amines 7-9 were first prepared from enantioenriched crotylsilane 418 via asymmetric 
crotylation of a variety of Alloc imines, generated in situ from aldehydes 5a-c and allyl carbamate (6). 
Scheme 3. Synthesis of enantioenriched homoallylic amines 7-9. 
 
After Pd(0)-mediated Alloc deprotection, the amines were coupled (HATU/DIPEA) to various 
Boc-protected D- and L-amino acids to afford Boc-protected substrate precursors 10a-g (Scheme 4 and 
Table 1). Removal of the Boc group with silica-supported TsOH (SCX) resin gave the deprotected amino 
esters 1a-g, which were immediately carried on to cyclization studies as the free base without further 
purification (Scheme 4).  
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Scheme 4. Conversion of homoallylic amines 7-9 to cyclization substrates 1a-g through Boc-protected 
intermediates 10a-g. 
 
Table 1. Yields of Boc-protected, enantioenriched homoallylic amine building blocks 10. 
entry starting  
material  
(R1) 
AA  
(from  
Boc-AA-OH) 
R2 (sidechain 
stereochemistry) 
product  
10 
yield 
of 10 
1 7 (Ph) L-Phe -CH2Ph (S) (S)-10a 49% 
2 7 (Ph) D-Phe -CH2Ph (R) (R)-10a 54% 
3 7 (Ph) L-Leu -CH2iPr (S) (S)-10b 52% 
4 7 (Ph) D-Leu -CH2iPr (R) (R)-10b 63% 
5 7 (Ph) L-Val -iPr (S) (S)-10c 83% 
6 7 (Ph) D-Val -iPr (R) (R)-10c 67% 
7 7 (Ph) L-Ala -CH3 (S) (S)-10d 69% 
8 7 (Ph) D-Ala -CH3 (R) (R)-10d 75% 
9 8 (3-BrPh) L-Phe -CH2Ph (S) (S)-10e 91% 
10 8 (3-BrPh) D-Phe -CH2Ph (R) (R)-10e 75% 
11 9 (CyPr) L-Phe -CH2Ph (S) (S)-10f 95% 
12 9 (CyPr) D-Phe -CH2Ph (R) (R)-10f 66% 
13 7 (Ph) L-Pro -CH2CH2CH2- (S) (S)-10g 73% 
14 7 (Ph) D-Pro -CH2CH2CH2- (S) (R)-10g 67% 
 
Initial substrate scope studies were performed on L-amino acid-derived (S)-10b, (S)-10c, and (S)-10d. 
Disappointingly, under microwave-mediated conditions, these substrates all produced intractable mixtures 
of what appeared to be three or more diastereomers of the pyrrolodiazepinone 3. We attributed these 
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mixtures to both a lack of diastereoselectivity in the pyrrolidine ring formation, as well as possible 
epimerization of the acidic amino acid α-center. We next attempted to identify milder conditions to improve 
diastereoselectivity using (S)-10b as a model substrate. In order to better understand the sequence of the 
three-step transformation, we first performed in situ NMR analysis following treatment of (S)-1b with DBU 
(CD3CN, room temperature) and observed that the unsaturated amide rapidly isomerizes to the conjugated 
isomer (S)-11b (Scheme 5). Accordingly, we initially envisioned the reaction occurring through one of two 
three-step sequences: Pathway A entails double bond isomerization to (S)-11b, followed by intramolecular 
lactamization and subsequent transannular cyclization13 of macrocycle (S)-12b; conversely in Pathway B, 
after isomerization to (S)-11b, an intramolecular aza-Michael reaction would give pyrrolidine (S,S)-13b 
with subsequent 7-membered lactam formation to afford (S,S)-3b. On heating substrate (S)-1b to 100 °C in 
CD3CN with one equivalent of DBU, full disappearance of all olefinic protons was observed in 1H NMR, 
prior to complete lactamization (loss of methanol) as determined by LC/MS analysis of an aliquot taken at 
the same time point. We thus excluded macrocycle (S)-12b as a major intermediate, and presumed the three-
step sequence to predominantly occur via pyrrolidine (S,S)-13b (Pathway B).  
Scheme 5. Mechanistic pathways for pyrrolodiazepinone formation. 
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Pathway B thus renders the intramolecular aza-Michael reaction a key diastereodetermining event. 
Young and coworkers have shown that the diastereomeric control of intramolecular aza-Michael reactions 
to form six membered rings can be divergent, depending on the impact of reagents used and the sterics of 
the six-centered transition state.19-20 Analysis of the conformations preceding a five-centered transition state 
formation (Scheme 6) that would give rise to the two possible pyrrolidine diastereomers 13b suggests that 
the conformation producing the observed stereochemistry ((S,2S)-13b) lacks a disfavorable 1,3-diaxial 
interaction between the methyl substituent and the vinylic C-H of the Michael acceptor, which is present in 
the conformation giving rise to the analogous product ((S,2R)-13b).  
Scheme 6.  Kinetic rationale for favored pyrrolidine cyclization. 
 
Despite this possible kinetic rationale for diastereoselectivity, the observation of more than two 
diastereomers under forcing conditions implied epimerization at the acidic amino acid α-center along with 
a possible via retro-aza-Michael processes to thermodynamically equilibrate the pyrrolidine chiral center; 
similar processes have been demonstrated in the literature.21-24 For simplification, we first focused on 
potential thermodynamic equilibration of the pyrrolidine, using DFT analysis25 (B3LYP-6-31g**) in order 
to compare the relative Gibbs free energies of the possible product and intermediate diastereomers for the 
intermediate pyrrolidines 13 (Table 2).  
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Table 2. DFT-calculated (B3LYP/6-31G**) relative energiesa of pyrrolidine diastereomers arising from 
cyclization Pathway B from either L- or D-amino acid-derived substrates 1. 
 
entry starting 
material 
relative energies for diastereomers 
of pyrrolidines 13 (kcal/mol)a 
from L-AAs from D-AAs 
(S,2S) (S,2R) (R,2R) (R,2S) 
1 1a +1.4 0 +1.0 0 
2 1b +0.1 0 +0.6 0 
3 1c 0 +1.3 +1.7 0 
4 1d 0 +0.02 0 +0.4 
(a) Energy differences are reported as the Gibbs free energy differences (in kcal/mol) for pyrrolidine diastereomeric pairs with 
similar amino acid-sidechain stereochemistry, and were calculated with Jaguar (Schrodinger, Inc.) on DFT-optimized structures 
in the absence of solvent. 
Our DFT calculations indicate that there is no consistent trend for thermodynamic control of the 
intermediate pyrrolidine stereochemistry; the (2R) or (2S) diastereomer is thermodynamically favorable to 
varying degrees, depending on amino acid sidechain composition and stereochemistry. We postulated, then, 
that conditions disfavorable to the thermodynamic equilibration of 13 should give rise to improved 
diastereoselectivity, in the formation of the kinetically favored (2S) product for other substrates. Our efforts 
to optimize the reaction parameters for substrate (S)-1b according to this assumption are summarized in 
Table 3. In agreement with our kinetic hypothesis, lowering the reaction temperature to 60 °C did improve 
diastereoselectivity, albeit with slower conversion (48 h reaction times). Rate enhancement through 
increased equivalents of DBU also gave a remarkable improvement in diastereoselectivity at 25 °C, but 
there was still limited conversion to product after 18 h. Gratifyingly, heating the same conditions to 100 °C 
gave the desired product in 91% yield after 90 minutes, with a negligible drop in diastereoselectivity in 
comparison to the room temperature conditions. 
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Table 3. Optimization of conditions intended to favor kinetic pyrrolidine intermediate (S,2S)-11b gives rise to 
improved d.r. of final product (S,S)-3b at high percent conversion. 
 
entry equiv. 
DBU 
temp (°C) time (h) % 3b d.r. 
1 1.0 145a 0.75 100c 11:3:1f 
2b 1.0 60 48 87d 6:1e 
3 5.0 25 18 53c 22:1f 
4 5.0 100 1.5 91c 17:1f 
(a) Microwave heating; (b) CD3CN solvent; (c) % conversion determined by UPLC-MS analysis; (d) % conversion determined by 
1H NMR; (e) determined by in situ 1H NMR of reaction mixture; (f) determined by 1H NMR of isolated product. 
We next explored the scope and diastereoselectivity of these improved conditions on a range of 
other substrates; the results are summarized in Figure 2. The transformation proceeded smoothly for 
substrates substituted with both aliphatic and aromatic L-amino acid sidechains. Notably, L-valine derived 
substrate (S)-1c produced bicyclic compound (S,S)-3c with no other diastereomers detected; this outcome 
can potentially be rationalized by the DFT calculations, as the two L-valine pyrrolidines were the only 
observed case wherein the (2S) (kinetic) pyrrolidine is also significantly thermodynamically favored 
relative to the (2R) pyrrolidine (by approximately 1.3 kcal/mol). We propose that this 
kinetic/thermodynamic match leads to the exclusive formation of only one diastereomer. We also examined 
one D-amino acid-derived substrate, D-leucine substituted (R)-1b. Disappointingly, under the optimized 
conditions this substrate produced an inseparable mixture of two diastereomers with a significantly poorer 
d.r of 3:1, which curiously appeared to favor the same (S,S)-3b product that was obtained from (S)-1b. 
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Figure 2. Scope and products of DBU-mediated cyclization. Yields are reported over two steps (Boc deprotection, 
cyclization) from Boc-protected precursors 10. Diastereomeric ratios are reported for purified products with reported 
isolated yields; in some cases crude NMR analysis indicated additional diastereomers had formed but were resolved 
chromatographically, see Experimental Section for details. 
 
In an effort to identify conditions that would impart improved diastereoselectivity for the D-amino 
acid derived substrates, we next examined NaOMe, a strong base capable of effecting double bond 
isomerizations, aza-Michael reactions, and transamidations.26 Treatment of substrate (R)-1b with NaOMe 
in both THF and DMF at -78 °C rapidly afforded the desired pyrrolodiazepinone in excellent yields. As 
compared to the DBU conditions, treating (R)-1b with sodium methoxide and THF as solvent shifted the 
product ratio to a 1.4:1 mixture of (S,S)-3b and (R,R)-3b (Table 4, Entry 2). Interestingly, the ratio shifted 
to favor the (R,R)-3b diastereomer with the use of sodium methoxide and DMF as solvent (Table 4, Entry 
3). In contrast to the diastereodivergence observed with the (R)-substrates, the L-amino acid-derived 
substrates (S)-1a and (S)-1b produced the same major diastereomers (S,S)-3a and (S,S)-3b under the 
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NaOMe conditions as had been observed previously under the DBU conditions, albeit with differing 
degrees of diastereoselectivity (Table 4, Entries 4 and 5, and Figures 2 and 3).  
Table 4. Condition-dependent outcomes of pyrrolodiazepinone formation on L- and D-leucine substrates 10b. 
 
entry starting 
material 
conditions yield 3b ratio 
(S,S):(R,R) 
1 (R)-10b DBU/CH3CNa 72% 3:1 
2 (R)-10b NaOMe/THFb 92% 1.4:1 
3 (R)-10b NaOMe/DMFc 94% 1:8 
4 (S)-10b DBU/CH3CNa 72% 17:1 
5 (S)-10b NaOMe/DMFc 65% 4:1 
 
(a) Conditions: 5 equiv. DBU, CH3CN (0.1M), 100 °C, 2 h; (b) Conditions: 2 equiv. NaOMe, THF (0.1M), 25 °C, 1h; (c) 
Conditions: 2 equiv. NaOMe, DMF (0.1M), 25 °C, 1 h 
Using the optimized NaOMe/DMF conditions, similar reactivity favoring the (R,R) diastereomer 
was observed with other D-amino acid substrates (R)-1a, and (R)-1c-f as summarized in Figure 3. In 
summary, these results suggested that following an initial aza-Mannich reaction and subsequent 
macrolactamization, epimerization of the amino acid α-center occurs to afford only two of four possible 
diastereomeric bicyclic cores as major products in varying ratios, dependent upon both stereochemistry of 
substrate and the conditions used. 
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Figure 3. Scope and products of the NaOMe-mediated cyclization. Yields are reported over two steps (Boc 
deprotection, cyclization) from Boc-protected precursors 10. Diastereomeric ratios are reported for purified 
products. 
In order to determine a possible cause for the observed diastereodivergent pathways, we performed 
additional DFT calculations examining the relative thermodynamic stabilities of the product diastereomers 
3. These relative energy values are presented in Table 5; in all cases, the (R,R) diastereomer is the 
thermodynamically most stable, followed by the (S,S) diastereomer which is only slightly (≤0.5 kcal/mol) 
higher in energy. The remaining two diastereomers, which were not cleanly isolated under any conditions 
examined for these substrates, are considerably higher in energy. 
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Table 5. DFT-calculated (B3LYP-6-31g**) relative energies of pyrrolodiazepinone diastereomers arising from 
cyclization Pathway B from either L- or D-amino acid-derived substrates 1.  
 
Entry Starting 
Material 
Relative energiesa for diastereomers 
of pyrrolodiazepinones 3 (kcal/mol) 
(5S,9aS) (5S,9aR) (5R,9aR) (5R,9aS) 
1 1a +0.4 +1.8 0 +1.2 
2 1b +0.5 +2.3 0 +2.5 
3 1c +0.5 +1.3 0 +0.9 
4 1d +0.3 +2.0 0 +1.2 
a) Relative energies are reported as Gibbs free energy differences in kcal/mol and were calculated with Jaguar (Schrodinger, Inc.) 
on DFT-optimized (B3LYP/6-31G**) structures in the absence of solvent. 
Based on these trends, our proposed mechanistic scheme depicting the envisioned global equilibria 
is presented in Scheme 7. From diastereomers (S)-1b/(R)-1b, following the initial pyrrolidine formation 
step (presumed to kinetically favor the cis product in all cases), the possibility of thermodynamic 
equilibration at each intermediate allows for the funneling into one of two thermodynamic wells: the 
observed products (S,S)-3b and (R,R)-3b. The degree of thermodynamic equilibration that occurs at each 
step, presumably mediated by several factors including sterics, base strength, ring strain and solvent effects, 
ultimately determines the final diastereomeric distribution. For substrate (S)-1b, the kinetically favored 
pyrrole cyclizes to give thermodynamically favored product (S,S)-3b, representing a “matched” scenario. 
The compound (R,R)-3b, obtained via lactamization of the thermodynamically favored pyrrole (R,2R)-11b, 
has two potential downhill routes for equilibration: (1) a retro-aza-Michael/aza-Michael pathway to give 
rise to the observed major diastereomer (S,S)-3b, or (2) α-epimerization of the amino acid center to give 
compound (R,R)-3b, the observed minor diastereomer. Conversely, D-leucine-coupled substrate (R)-2b 
undergoes a kinetically favored cyclization to give intermediate (R,2S)-11b, which has a larger 
thermodynamic driving force (0.6 kcal/mol) for retro-aza-Michael epimerization of the pyrrolidine 
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intermediate than its (S)-diastereomer, as well as two energetically downhill epimerization pathways away 
from (R,S)-3b, one producing (S,S)-3b, the other producing (R,R)-3b. In contrast, conditions favoring the 
thermodynamic equilibration to pyrrolidine (R,2R)-11b would then, upon lactamization, produce bicyclic 
product (R,R)-3b, a thermodynamic well. Reaction conditions optimized to favor the “kinetic” pyrrolidine 
formation for the (S)-isomer lead to a kinetic/thermodynamic mismatch for the (R)-isomer, with product 
ratios dependent upon the proportion of substrates progressing along the two thermodynamically downhill 
epimerizations. While it is difficult to attribute the improved (R)-isomer diastereomeric ratios under the 
NaOMe/DMF conditions, it may be that the increased basicity enables the intermediate pyrrole (R)-11b to 
equilibrate more rapidly to the highly thermodynamically-favored (R,2R)-11b product, improving 
diastereoselectivity toward the final product (R,R)-3b. Similar base-dependent processes leading to 
diastereodivergent reaction outcomes have been reported by Bradshaw and coworkers in the 
diastereodivergent construction of 5-oxodecahydroquinolines via intramolecular aza-Michael reactions,27 
as well as Galvez and coworkers in the Wadsworth-Emmons construction of alkylidinepiperidines.28 
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Scheme 7. Divergent reaction and equilibrium pathways leading to (S,S)-3b or (R,R)-3b as the predominant 
thermodynamically-favored products for substrates (S)-1b and (R)-1b, respectively. 
 
Energies and energy differences are reported as relative Gibbs free energies in kcal/mol and were calculated with Jaguar 
(Schrodinger, Inc.) on DFT-optimized (B3LYP/6-31G**) structures in the absence of solvent. 
As a final study, we examined the reactivity of proline-substituted substrates 1g under our 
optimized sets of conditions (Table 6). Following Boc deprotection and cyclization, L-proline-derived 
substrate (S)-10g afforded the expected compound (S,S)-3g as the major product under both sets of 
conditions. In addition, D-proline-derived substrate (R)-10g reacted as expected under the sodium 
methoxide conditions, affording compound (R,R)-3g in 50% yield with 4:1 diastereoselectivity. However, 
in contrast to all of the substrates derived from acyclic D-amino acids, (R)-10g produced a third distinct 
diastereomer as a major product when subjected to the DBU/CH3CN conditions. This diastereomer was 
assigned as (5aR,11aS)-3g based on 2D NMR analysis and DFT-predicted NMR spectra.1  
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Table 6. Condition-dependent pyrrolodiazepinone-formation on L- and D-proline substrates 10g. 
 
entry starting 
material 
conditions yield 3g ratio 
(S,S):(R,R): 
(R,S):(S,R) 
1 (S)-10g Aa 75% 14:1:0:0 
2 (S)-10g Bb 61% 14:1:1:0 
3 (R)-10g Aa 50% 1:1:4:0 
4 (R)-10g Bb 59% 21:87:1:0 
(a) Condition A: 5 equiv. DBU, CH3CN (0.1M), 100 °C, 2 h;  
(b) Condition B: 2 equiv. NaOMe, DMF (0.1M), 25 °C, 1 h. 
 
Revisiting the global equilibria as depicted in Scheme 7, we hypothesize that for proline-derived 
substrates, the constrained pyrrolidine ring creates sufficient steric congestion to prevent the α 
epimerization of the amino acid center by the more hindered, weaker base DBU, thus preventing the 
conversion of (5aR,11aS)-3g to (5aS,11aS)-3g as is postulated to occur under DBU-mediated conditions 
with other D-amino acid sidechains (Scheme 8). Consistent with this hypothesis, we found that treatment 
of isolated (5aR,11aS)-3g with NaOMe in DMF (a less hindered, stronger base) quantitatively produces 
(5aS,11aS)-3g as a major product. In this experiment, there was no discernable change in the quantified 
amount of (5aR,11aR)-3g in the resultant diastereomeric mixture, suggesting that for this substrate, the α-
epimerization is kinetically favored relative to the retro-aza-Michael epimerization to (5aR,11aR)-3g, 
which is slightly more thermodynamically downhill (0.6 kcal/mol vs. 1.0 kcal/mol).  
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Scheme 8. Divergent diastereoselectivities for major observed diastereomers of proline-derived substrates 1g. 
 
Energy differences are reported as relative Gibbs free energies in kcal/mol and were calculated with Jaguar (Schrodinger, Inc.) on 
DFT-optimized (B3LYP/6-31G**) structures in the absence of solvent. 
CONCLUSION 
 
In summary, we have developed a highly modular and diastereodivergent route to chiral 
pyrrolodiazepinones. Diastereoselectivity in this efficient three-step transformation can be tuned by the 
selection of starting material stereochemistry and reaction conditions to afford to distinct diastereomers of 
this underexplored bicyclic, peptidomimetic heterocycle. Efforts to further utilize this unique tandem 
transformation in the context of diversity oriented library synthesis and peptidomimetic applications 
including pyrrolodiazepinone libraries are currently underway and will be reported in due course. 
EXPERIMENTAL SECTION 
1. General information. All 1H NMR and 13C NMR spectra were recorded using Varian Unity Plus 400 or 
Varian Unity Plus 500 spectrometers at ambient temperature. Chemical shifts are reported in parts per 
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million as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
br = broad), coupling constant and integration. Infrared spectra were recorded on Nicolet Nexus 670 FT-IR 
ESP spectrophotometer. Optical rotations were recorded on an AUTOPOL III digital polarimeter at 589 nm 
and reported as [α]23D (concentration in g/100 mL solvent). High resolution mass spectrometry data was 
obtained on a Waters Qtof (hybrid quadrupolar/time-of-flight) API US system by electrospray (ESI) in the 
positive mode. Mass correction was done by an external reference using a Waters Lockspray accessory. 
Analytical thin layer chromatography was performed using EMD 0.25 mm silica gel 60-F plates. Flash 
column chromatography was performed on Sorbent Technologies 60 Å silica gel. All reactions were 
performed under an atmosphere of nitrogen or argon with magnetic stirring. Dichloromethane and 
tetrahydrofuran were obtained from a dry solvent system (alumina). Anhydrous acetonitrile and 
dimethylformamide were obtained from Sigma-Aldrich and used without further purification. SiliaBond® 
Tosic Acid (SCX) resin was obtained from Silicycle, Inc. Macroporous Tosic Acid (MP-TsOH) resin was 
obtained from Waters, Inc. All microwave experiments were performed on a CEM Discover microwave 
reactor, using a sealed 10- or 35-mL vessel with temperatures monitored by an external sensor. 
General Procedure A: To a flame-dried, nitrogen-purged flask equipped with a stir bar was added allyl 
carbamate (1.0 equiv). Anhydrous CH2Cl2 was added, followed by the requisite aldehyde 5a, 5b, or 5c. The 
reaction mixture was cooled to -78 °C and BF3-diethyl etherate was slowly added via syringe. The reaction 
was stirred at -78 °C for 30 minutes. Crotylsilane 4 was added and the reaction vessel was transferred to a 
chiller set to -35 °C. The reaction was stirred at this temperature for 48-72 h, tracking by TLC analysis. 
Upon completion, the reaction mixture was carefully quenched with the addition of saturated aqueous 
sodium bicarbonate and extracted three times with CH2Cl2. The combined organic fractions were washed 
with brine, dried over sodium sulfate, and condensed to give a crude product that was then purified by ISCO 
flash column chromatography using a prepacked 80 g silica cartridge. Products were eluted using a gradient 
20 
 
of 15%-27% ethyl acetate in hexanes over 15 minutes, followed by 40% ethyl acetate in hexanes for 5 
minutes.  
Methyl (5S,6R,E)-6-(((allyloxy)carbonyl)amino)-5-methyl-6-phenylhex-3-enoate (7). Obtained as a clear 
oil (1.16 g, 90% yield, 10:1 d.r.) from benzaldehyde 5a utilizing General Procedure A. [α]23D +38 (c 0.39, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.24-7.16 (m, 2H), 7.16-7.10 (m, 3H), 5.81 (s, 2H), 5.46 (td, J = 
6.6, 15.4 Hz, 1H), 5.27 (dd, J = 8.0, 15.4 Hz, 1H), 5.19 (d, J = 16.8 Hz, 1H), 5.08 (d, J = 10.6 Hz, 1H), 
4.58 (t, J = 7.4 Hz, 1H), 4.48 (dd, J = 5.9, 13.3 Hz, 1H), 4.41 (dd, J = 4.3, 13.3 Hz, 1H), 3.57 (s, 3H), 2.91 
(d, J = 6.6 Hz, 2H), 2.56 (tdd, J = 7.0, 7.4, 8.0 Hz, 1H), 0.92 (d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, 
CDCl3) δ 171.7, 155.2, 140.0, 135.2, 127.7, 126.9, 126.7, 123.0, 117.0, 65.0, 58.9, 51.4, 41.6, 37.3, 16.2. 
HRMS (m/z): [M+Na]+ calcd. for C18H23NO4Na, 340.1525; found, 340.1528. IR (thin film): 3338, 1770, 
1700 cm-1. 
Methyl (5S,6R,E)-6-(((allyloxy)carbonyl)amino)-6-(3-bromophenyl)-5-methylhex-3-enoate (8). Obtained 
as a clear oil (2.21 g, 73% yield, >20:1 d.r.) from 3-bromobenzaldehyde 5b utilizing General Procedure A. 
[α]23D +71 (c 4.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 7.6 Hz, 1H), 7.32 (s, 1H), 7.17 (t, J = 
7.6 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 5.85 (tdd, J = 5.6, 10.2, 16.7 Hz, 1H), 5.52 (td, J = 6.6, 15.6 Hz, 1H), 
5.27 (dd, J = 8.0, 15.6 Hz, 1H), 5.24 (d, J = 16.7 Hz, 1H), 5.14 (br d, J = 10.2 Hz, 1H), 4.57 (dd, J = 7.0, 
8.6 Hz, 1H), 4.51 (br dd, J = 5.5, 13.5 Hz, 1H), 4.46 (dd, J = 5.5, 13.5 Hz, 1H), 3.63 (s, 3H), 2.97 (d, J = 
6.6 Hz, 2H), 2.55 (qd, J = 7.0, 8.0 Hz, 1H), 0.93 (d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 
171.9, 155.3, 142.6, 135.7, 134.8, 132.6, 130.0, 129.5, 125.8, 123.8, 122.1, 117.5, 65.5, 58.5,51.7, 41.6, 
37.4, 16.3. HRMS (m/z): [M+Na]+ calcd. for C18H22BrNO4Na, 418.0630; found, 418.0623. IR (thin film): 
3328, 1700, 1527 cm-1. 
Methyl (5S,6S,E)-6-(((allyloxy)carbonyl)amino)-6-cyclopropyl-5-methylhex-3-enoate (9). Obtained as a 
clear oil (2.11 g, 98% yield, 12:1 d.r.) from cyclopropanecarbaldehyde 5c utilizing General Procedure A. 
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[α]23D -24 (c 9.3, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.78 (tdd, J = 5.5, 10.5, 17.0 Hz, 1H), 5.48-5.42 
(m, 2H), 5.15 (dd, J = 1.2, 17.0 Hz, 1H), 5.09-5.02 (m, 2H), 4.40 (br d, J = 5.5 Hz, 2H), 3.54 (s, 3H), 2.93 
(d, J = 5.0 Hz, 2H), 2.91-2.82 (m, 1H), 2.34 (sxt, J = 6.2 Hz, 1H), 0.96 (d, J = 7.0 Hz, 3H), 0.66 (dtd, J = 
4.3, 8.2, 12.9 Hz, 1H), 0.46-0.34 (m, 1H), 0.30-0.19 (m, 1H), 0.19-0.10 (m, 2H). 13C{1H} NMR (100 MHz, 
CDCl3) δ 171.9, 155.6, 135.9, 132.8, 122.3, 116.8, 64.9, 58.9, 51.4, 41.8, 37.4, 16.4, 12.8, 4.5, 1.3. HRMS 
(m/z): [M+Na]+ calcd. for C15H23NO4Na, 304.1525; found, 304.1524. IR (thin film): 3334, 1697, 1524 cm-
1. 
General Procedure B: Alloc Deprotection. Alloc-protected substrate 7, 8, or 9 was dissolved in a 3:1 
CH2Cl2:CH3OH solution (final concentration 0.4 M). 1,3-dimethylbarbituric acid (1.1 equiv) was added 
and the reaction was stirred for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (5 mol %) was added 
in one portion and the reaction was stirred at room temperature until TLC analysis indicated full 
consumption of starting material (approximately 2 h). MP-TsOH resin (3 mmol/g resin loading, 4 equiv, 
1.2 grams resin per millimole substrate) was added in one portion and the reaction was stirred at room 
temperature for one hour. The resin was isolated by filtration, rinsing three times with CH2Cl2. After 
returning the resin to the flask, a solution of 10% Et3N in CH3OH (10 mL per gram of resin) was added. 
The suspension was stirred for one hour, filtered and the one hour resin treatment was repeated with a fresh 
portion of 10% Et3N in methanol followed by another filtration. Both mother liquors were combined and 
condensed to give the intermediate deprotected amines S1-S3 as orange oils. Compounds S1-S3 were not 
shelf-stable and were carried on to the amino acid coupling step immediately without further purification. 
General Procedure C: HATU-mediated coupling. Compounds S1-S3 were dissolved in CH2Cl2 (0.2M 
concentration) at room temperature under an atmosphere of nitrogen. The requisite Boc-protected amino 
acid (1.1 equiv) was added, followed by HATU (1.2 equiv) and N,N-diisopropylethylamine (2.5 equiv). 
After stirring at room temperature overnight, the reaction was condensed onto silica gel and purified by 
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ISCO flash chromatography using a gradient of 30% to 50% ethyl acetate in hexanes (over the default 
runtime for the size column used) to give amino acid-protected substrates 10a-g. 
Methyl (5S,6R,E)-6-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-5-methyl-6-phenylhex-3-
enoate ((S)-10a). Obtained as a pale yellow solid (300 mg, 49% yield, two steps) after deprotection of 
compound 7 to afford compound S1 (General Procedure B), which was immediately coupled with Boc-L-
phenylalanine (General Procedure C). mp = 105-107 °C; [α]23D +117 (c 3.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) 5.4:1 mixture of Boc rotamers. Major Rotamer: δ 7.29-7.16 (m, 8H), 7.10-7.05 (m, 2H), 6.77 (br d, 
J = 7.8 Hz, 1H), 5.28-5.19 (m, 2H), 5.15 (br d, J = 8.6 Hz, 1H), 4.80 (br dd, J = 5.1, 7.4 Hz, 1H), 4.40 (br 
td, J = 6.6, 8.6 Hz, 1H), 3.68 (s, 3H), 3.10-2.96 (m, 3H), 2.94 (d, J = 7.0 Hz, 2H), 1.38 (s, 9H), 0.84 (m, 
3H); Minor Rotamer: δ 7.77 (d, J = 7.8, 1H), 7.70 (d, J = 7.8, 1H), 7.45-7.34 (m, 3H), 7.29-7.16 (m, 1H), 
7.15-7.13 (m, 2H), 7.13-7.11 (m, 1H), 5.48-5.38 (m, 2H), 5.12-5.05 (m, 2H), 4.78-4.73 (m, 1H), 4.60 (brq, 
J = 5.9 Hz, 1H), 3.68 (s, 3H), 3.21 (dd, J = 5.9, 14.5 Hz, 1H), 3.10-2.96 (m, 1H), 2.92-2.89 (m, 1H), 2.86 
(ddd, J = 1.6, 7.8, 16.0 Hz, 1H), 2.71 (ddd, J = 1.4, 7.1, 16.0 Hz, 1H), 1.37 (s, 9H), 0.84 (m, 3H); 13C{1H}  
NMR (100 MHz, CDCl3, mixture of rotamers, all peaks reported) δ 174.0, 172.4, 170.8, 170.3, 155.4, 155.2, 
139.2, 139.0, 136.8, 136.2, 135.4, 134.4, 129.4, 128.5, 128.4, 128.0, 127.5, 127.5, 127.1, 126.8, 126.5, 
126.0, 123.7, 121.8, 117.3, 111.0, 80.0, 79.8, 57.6, 56.9, 56.0, 54.2, 52.1, 51.9, 41.6, 38.4, 37.9, 37.3, 36.5, 
32.7, 29.6, 28.2, 17.5, 16.5; HRMS (m/z): [M+Na]+ calcd. for C28H36N2O5Na, 503.2522; found, 503.2534. 
IR (thin film): 3315, 1738, 1698, 1655, 745, 700 cm-1. 
Methyl (5S,6R,E)-6-((R)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-5-methyl-6-phenylhex-3-
enoate ((R)-10a). Obtained as a pale yellow solid (335 mg, 54% yield, two steps) after deprotection of 
compound 7 to afford compound S1 (General Procedure B), which was immediately coupled with Boc-D-
phenylalanine (General Procedure C). mp 110-112 °C; [α]23D +3.6 (c 4.7, CHCl3); 1H NMR (400 MHz, 
CDCl3) 5:1 mixture of Boc rotamers. Major Rotamer: δ 7.30-7.08 (m, 8H), 7.06-6.95 (m, 2H), 6.85 (br d, 
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J = 8.2 Hz, 1H), 5.55-5.47 (m, 1H), 5.41 (td, J = 7.0, 15.6 Hz, 1H), 5.26 (d, J = 8.2, 15.6 Hz, 1H), 4.90 (dd, 
J = 6.6, 8.6 Hz, 1H), 4.48-4.36 (m, 1H), 3.96 (s, 3H), 3.11-2.91 (m, 4H), 2.57 (sxt, J = 6.9 Hz, 1H), 1.46-
1.35 (m, 9H), 0.9 (d, J = 6.9 Hz, 1H); Minor Rotamer: δ 7.78 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 
7.46-7.37 (m, 2H), 7.30-7.08 (m, 6H), 5.55-5.45 (m, 1H), 5.21-5.16 (m, 1H), 5.11 (d, J = 8.2 Hz, 1H), 4.62 
(q, J = 7.0 Hz, 1H), 3.72 (s, 3H), 3.22 (dd, J = 5.0, 13.7 Hz, 1H), 3.11-2.91 (m, 3H), 2.85-2.78 (m, 1H), 
1.46-1.35 (m, 9H), 0.93 (d, J = 6.6 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3, mixture of rotamers, all 
peaks reported) δ 174.3, 172.9, 172.7, 171.0, 170.7, 155.6, 155.3, 140.5, 139.0, 138.8, 136.7, 136.2, 135.4, 
134.7, 129.4, 128.5, 128.1, 127.4, 127.2, 126.9, 126.7, 123.8, 122.0, 117.3, 111.2, 80.0, 79.9, 57.5, 57.0, 
56.9, 56.0, 54.3, 52.0, 51.9, 41.6, 38.2, 38.0, 37.4, 36.7, 32.9, 28.3, 17.8, 16.3 HRMS (m/z): [M+Na]+ calcd. 
for C28H36N2O5Na, 503.2522; found, 503.2518. IR (thin film): 3308, 1714, 1521, 734, 700, 667 cm-1. 
Methyl (5S,6R,E)-6-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-5-methyl-6-phenylhex-3-
enoate ((S)-10b). Obtained as an amorphous yellow solid (275 mg, 52% yield, two steps) after deprotection 
of compound 7 to afford compound S1 (General Procedure B), which was immediately coupled with Boc-
L-leucine (General Procedure C). [α]23D -3.6 (c 2.4, CHCl3); 1H NMR (400 MHz, CDCl3) 7:1 mixture of 
Boc rotamers. Major Rotamer: δ 7.31-7.24 (m, 2H), 7.23-7.18 (m, 1H), 7.17-7.13 (m, 2H), 7.07 (br d, J = 
7.4 Hz, 1H), 5.51 (td, J = 7.0, 15.6 Hz, 1H), 5.31 (dd, J = 8.0, 15.6 Hz, 1H), 4.91 (dd, J = 6.3, 9.0 Hz, 1H), 
4.21-4.08 (m, 1H), 3.66 (s, 3H), 3.01-2.97 (m, 2H), 2.60 (sxt, J = 6.8 Hz, 1H), 1.80-1.50 (m, 3H), 1.42 (s, 
9H), 0.93 (d, J = 6.8 Hz, 3H), 0.89-0.84 (m, 6H); Minor Rotamer δ 7.44 (br d, J = 8.6 Hz, 1H), 7.31-7.24 
(m, 2H), 7.23-7.18 (m, 1H), 7.17-7.13 (m, 2H), 5.53-5.45 (m, 1H), 5.29-5.20 (m, 1H), 5.03 (br d, J = 8.6 
Hz, 1H), 4.87 (dd, J = 5.9, 8.6 Hz, 1H), 4.32 (dt, J = 5.1, 8.6 Hz, 1H), 3.68 (s, 3H), 3.05-3.01 (m, 1H), 2.99-
2.93 (m, 1H), 2.88-2.80 (m, 1H), 1.80-1.50 (m, 3H), 1.42 (s, 9H), 0.97-0.84 (m, 9H); 13C{1H} NMR (100 
MHz, CDCl3, mixture of rotamers, all peaks reported) δ 175.9, 172.6, 171.9, 155.9, 155.7, 139.6, 135.6, 
134.8, 128.0, 127.3, 127.0, 123.5, 121.8, 79.8, 57.2, 56.7, 53.1, 51.8, 41.7, 40.6, 37.4, 36.8, 32.8, 29.6, 28.2, 
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24.6, 22.8, 21.9, 17.8, 16.1; HRMS (m/z): [M+Na]+ calcd. for C25H38N2O5Na, 469.2678; found, 469.2682. 
IR (thin film): 3270, 1742, 1691, 1642, 701 cm-1. 
Methyl (5S,6R,E)-6-((R)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-5-methyl-6-phenylhex-3-
enoate ((R)-10b). Obtained as an off-white, amorphous solid (1.20 g, 63% yield over two steps) after 
deprotection of compound 7 to afford compound S1 (General Procedure B), which was immediately 
coupled with Boc-D-leucine (General Procedure C). [α]23D +46 (c 15.9, CHCl3); 1H NMR (400 MHz, 
DMSO-d6) 5:1 mixture of Boc rotamers. Major rotamer: δ 8.03 (br d, J = 9.4 Hz, 1H), 7.29-7.14 (m, 5H), 
6.9 (br d, J = 8.6 Hz, 1H). 5.36 (dd, J = 6.0, 15.2 Hz, 1H), 5.31 (dd, J = 6.0, 15.2 Hz, 1H), 4.69 (t, J = 8.4 
Hz, 1H), 3.98 (dt, J = 5.8, 9.0 Hz, 1H), 3.51 (s, 3H), 2.92 (dd, J = 6.6, 16.8 Hz, 1H), 2.86 (dd, J = 6.0, 16.8 
Hz, 1H), 2.60-2.50 (m, 1H), 1.55-1.41 (m, 1H), 1.36 (s, 9H), 1.35-1.26 (m, 2H), 0.93 (d, J = 7.0 Hz, 3H), 
0.81 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.3 Hz, 3H); Minor rotamer: δ 8.16 (br d, J = 9.0 Hz, 1H), 7.29-7.14 
(m, 5H), 6.90-6.85 (m, 1H), 5.27-5.26 (m, 2H), 4.62 (t, J = 9.0 Hz, 1H), 4.03-3.93 (m, 1H), 3.51 (s, 3H), 
2.89-2.82 (m, 1H), 2.65 (dd, J = 5.9, 17.6 Hz, 1H), 2.60-2.50 (m, 1H), 1.55-1.41 (m, 1H), 1.36 (s, 9H), 
1.35-1.26 (m, 2H), 0.95-0.90 (m, 3H), 0.85-0.75 (m, 6H); 13C{1H} NMR (100 MHz, DMSO-d6, mixture of 
rotamers, all peaks reported) δ 171.8, 171.4, 171.3, 155.3, 141.7, 136.0, 135.3, 127.8, 127.7, 127.1, 1270, 
126.5, 122.2, 120.9, 77.9, 56.7, 56.5, 53.1, 51.4, 51.3, 41.4, 40.5, 37.1, 32.1, 28.1, 24.2, 22.8, 21.7, 17.2, 
16.2; HRMS (m/z): [M+Na]+ calcd. for C25H38N2O5Na, 469.2678; found, 469.2670. IR (thin film): 3275, 
1738, 1681, 1646, 753, 698 cm-1. 
Methyl (5S,6R,E)-6-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-5-methyl-6-phenylhex-3-
enoate ((S)-10c). Obtained as a pale yellow solid (386 mg, 83% yield over two steps) after deprotection of 
compound 7 to afford compound S1 (General Procedure B), which was immediately coupled with Boc-L-
valine (General Procedure C). mp 107-111 °C; [α]23D +183 (c 1.65, CHCl3); 1H NMR (400 MHz, CDCl3) 
6.5:1 mixture of Boc rotamers. Major rotamer: δ 7.31-7.13 (m, 5H), 6.78 (br d, J = 7.8 Hz, 1H), 5.57 (dtd, 
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J = 1.2, 7.0, 15.6 Hz, 1H), 5.37-5.25 (m, 1H), 5.18 (br d, J = 7.8 Hz, 1H), 4.91 (dd, J = 5.5, 8.6 Hz, 1H), 
3.94 (dd, J = 6.3, 8.6 Hz, 1H), 3.71 (s, 3H), 3.07-3.02 (m, 2H), 2.59 (q, J = 7.0 Hz, 1H), 2.18-2.10 (m, 1H), 
1.42 (s, 9H), 0.93 (d, J = 6.6 Hz, 6H), 0.88 (d, J = 7.0 Hz, 3H); Minor rotamer: δ 7.31-7.13 (m, 5H), 6.99 
(br d, J = 6.3 Hz, 1H), 5.61-5.49 (m, 1H), 5.37-5.25 (m, 1H), 5.02 (br d, J = 8.2 Hz, 1H), 4.85 (dd, J = 6.3, 
8.2 Hz, 1H), 3.95-3.86 (m, 1H), 3.70 (s, 3H), 3.01-2.97 (m, 2H), 2.92-2.80 (m, 1H), 2.12-2.05 (m, 1H), 
1.40 (s, 9H), 0.98 (d, J = 7.0 Hz, 6H), 0.84 (d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3, mixture 
of rotamers, all peaks reported) δ 172.6, 170.6, 155.8, 139.3, 136.0, 134.6, 128.0, 127.4, 127.1, 123.7, 121.9, 
79.7, 60.1, 57.6, 56.7, 52.0, 47.8, 37.5, 32.8, 30.5, 28.3, 19.5, 17.6, 16.4; HRMS (m/z): [M+Na]+ calcd. for 
C24H36N2O5Na, 455.2522, found, 455.2523. IR (thin film): 3399, 1741, 1686, 1645, 700, 636 cm-1. 
Methyl (5S,6R,E)-6-((R)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)-5-methyl-6-phenylhex-3-
enoate ((R)-10c). Obtained as a pale yellow solid (309 mg, 67% yield, two steps) after deprotection of 
compound 7 to compound S1 (General Procedure B), which was immediately coupled with Boc-D-valine 
(General Procedure C).  mp 72-75 °C; [α]23D +53 (c 1.35, CHCl3); 1H NMR (400 MHz, CDCl3) 6:1 mixture 
of Boc rotamers. Major rotamer: δ 7.31-7.12 (m, 5H), 6.77 (br d, J = 9.0 Hz, 1H), 5.56 (td, J = 7.2, 15.2 
Hz, 1H), 5.30 (dd, J = 8.6, 15.2 Hz, 1H), 5.26-5.20 (m, 1H), 4.94 (dd, J = 5.9, 8.6 Hz, 1H), 3.93 (dd, J = 
6.6, 8.6 Hz, 1H), 3.70 (s, 3H), 3.09-2.96 (m, 2H), 2.61 (sxt, J = 6.6 Hz, 1H), 2.22-2.08 (m, 1H), 1.44 (s, 
9H), 0.94 (d, J = 7.0 Hz, 3H), 0.89 (br d, J = 5.9 Hz, 3H), 0.84 (d, J = 7.0 Hz, 3H); Minor rotamer: δ 7.31-
7.52 (m, 5H), 5.61-5.50 (m, 1H), 5.34-5.19 (m, 1H), 4.91-4.85 (m, 1H), 4.00 (dd, J = 5.9, 8.6 Hz, 1H), 3.74 
(s, 3H), 3.09-2.96 (m, 2H), 2.92-2.82 (m, 1H), 2.22-2.08 (m, 1H), 1.44 (s, 9H), 0.98-0.95 (m, 3H), 0.92-
0.89 (m, 3H), 0.79 (d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3, mixture of rotamers, all peaks 
reported) δ 172.6, 170.7, 156.0, 139.3, 135.6, 134.9, 128.1, 127.6, 127.4, 127.2, 124.0, 122.0, 79.6, 60.1, 
59.4, 57.3, 56.7, 52.4, 52.0, 41.8, 37.4, 36.5, 32.8, 31.3, 28.3, 19.4, 18.0, 17.6, 16.6; HRMS (m/z): [M+Na]+ 
calcd. for C24H36N2O5Na, 455.2522, found, 455.2525. IR (thin film): 3312, 1741, 1679, 1651, 702 cm-1. 
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Methyl (5S,6R,E)-6-((S)-2-((tert-butoxycarbonyl)amino) propanamido)-5-methyl-6-phenylhex-3-enoate 
((S)-10d). Obtained as a white foam (202 mg, 69% yield, two steps) after deprotection of compound 7 to 
afford compound S1 (General Procedure B), which was immediately coupled with Boc-L-alanine (General 
Procedure C). [α]23D +8 (c 3.7, CHCl3); 1H NMR (400 MHz, CDCl3) >10:1 mixture of Boc rotamers. Major 
rotamer reported. δ 7.29-7.11 (m, 5H), 7.03 (br d, J = 8.8 Hz, 1H), 5.54 (dtd, J = 0.8, 7.4, 15.6 Hz, 1H), 
5.31 (dd, J = 8.0, 15.6 Hz, 1H), 5.10 (br d, J = 7.8 Hz, 1H), 4.87 (dd, J = 5.6, 8.8 Hz, 1H), 4.24-4.13 (m, 
1H), 3.68 (s, 3H), 3.02 (d, J = 7.4 Hz, 2H), 2.59 (dqd, J = 5.6, 6.6, 8.0 Hz, 1H), 1.42 (s, 9H), 1.32 (d, J = 
7.0 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 172.5, 171.6, 155.6, 139.6, 135.8, 
128.1, 127.4, 127.1, 123.6, 80.0, 56.8, 52.0, 50.0, 41.8, 37.6, 28.3, 17.9, 16.4; HRMS (m/z): [M+Na]+ calcd. 
for C22H32N2O5Na, 427.2209; found, 427.2215. IR (thin film): 3321, 1737, 1712, 1662, 737, 702 cm-1. 
Methyl (5S,6R,E)-6-((R)-2-((tert-butoxycarbonyl)amino) propanamido)-5-methyl-6-phenylhex-3-enoate 
((R)-10d). Obtained as an orange oil (222 mg, 75% yield, two steps) after deprotection of compound 7 to 
afford compound S1 (General Procedure B), which was immediately coupled with Boc-D-alanine (General 
Procedure C). [α]23D +3 (c 4.45, CHCl3); 1H NMR (400 MHz, CDCl3) >10:1 mixture of Boc rotamers. Major 
rotamer reported. δ 7.31-7.12 (m, 5H), 6.99 (br d, J = 8.2 Hz, 1H), 5.51 (dtd, J = 0.8, 7.4, 15.6 Hz, 1H), 
5.36-5.28 (m, 1H), 5.32 (dd, J = 7.8, 15.6 Hz, 1H), 4.51 (dd, J = 6.0, 8.4 Hz, 1H), 4.25-4.12 (m, 1H), 3.67 
(s, 3H), 3.02-2.98 (m, 2H), 2.61 (qdd, J = 6.6, 7.4, 8.4 Hz, 1H), 1.43 (br s, 9H), 1.30 (br d, J = 6.6 Hz, 3H), 
0.92 (d, J = 6.6 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3, mixture of rotamers, all peaks reported) δ 172.7, 
171.8, 155.7, 139.6, 134.7, 128.3, 128.2, 127.3, 127.1, 123.5, 121.9, 79.9, 57.2, 56.6, 52.2, 51.9, 50.1, 41.7, 
37.4, 36.7, 32.9, 28.3, 17.9, 16.1; HRMS (m/z): [M+Na]+ calcd. for C22H32N2O5Na, 427.2209; found, 
427.2204. IR (thin film): 3310, 1652, 1518 752, 700 cm-1. 
Methyl (5S,6R,E)-6-(3-bromophenyl)-6-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-5-
methylhex-3-enoate ((S)-10e). Obtained as a colorless foam (1.26 g, 91% yield, two steps) after deprotection 
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of compound 8 to compound S2 (General Procedure B), which was immediately coupled with Boc-L-
phenylalanine (General Procedure C). [α]23D +41 (c 4.2, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.32 (br d, 
J = 7.8 Hz, 1H), 7.25-7.19 (m, 4H), 7.15 (br d, J = 6.6 Hz, 2H), 7.10 (t, J = 7.8 Hz, 1H), 7.01 (d, J = 7.4 
Hz, 1H), 6.78 (br d, J = 8.2 Hz, 1H), 5.26 (dd, J = 7.0, 15.6 Hz, 1H), 5.21 (d, J = 8.2 Hz, 1H), 5.10 (dd, J 
= 9.0, 15.6 Hz, 1H), 4.73 (br dd, J = 5.5, 8.2 Hz, 1H), 4.38 (ddd, J = 6.0, 7.5, 8.2 Hz, 1H), 3.66 (s, 3H), 
3.05 (dd, J = 6.0, 13.5 Hz, 1H), 2.98 (dd, J = 7.5, 13.5 Hz, 1H), 2.94 (d, J = 7.0 Hz, 2H), 2.32 (dqd, J = 5.5, 
6.5, 9.0 Hz, 1H), 1.38 (s, 9H), 0.83 (br d, J = 6.5 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 172.1, 170.3, 
155.3, 141.8, 136.6, 135.0, 130.3, 130.1, 129.5, 129.2, 128.5, 126.7, 126.1, 124.0, 122.1, 79.9, 56.4, 55.8, 
51.9, 41.4, 38.1, 37.2, 28.1, 16.4. HRMS (m/z): calcd. for, C28H35BrN2O5Na 581.1627; found, 581.1616. 
IR (thin film): 3311, 1702, 1658, 779, 699 cm-1. 
Methyl (5S,6R,E)-6-(3-bromophenyl)-6-((R)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-5-
methylhex-3-enoate ((R)-10e). Obtained as a colorless foam (420 mg, 75% yield, two steps) after 
deprotection of compound 8 to compound S2 (General Procedure B), which was immediately coupled with 
Boc-D-phenylalanine (General Procedure C). [α]23D +74 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.33 
(d, J = 7.8 Hz, 1H), 7.24-7.18 (m, 2H), 7.18-7.07 (m, 6H), 6.94 (br d, J = 7.4 Hz, 1H), 6.87 (br d, J = 7.4 
Hz, 1H), 5.44 (br d, J = 9.0 Hz, 1H), 5.39 (td, J = 7.0, 15.6 Hz, 1H), 5.22 (dd, J = 8.2, 15.6 Hz, 1H), 4.82 
(br dd, J = 6.6, 9.0 Hz, 1H), 4.39 (t, J = 7.4 Hz, 1H), 3.66 (s, 3H), 2.99 (br d, J = 7.4 Hz, 2H), 2.95 (d, J = 
7.0 Hz, 2H), 2.50 (qd, J = 6.6, 8.2 Hz, 1H), 1.39 (br s, 9H), 0.89 (d, J = 6.6 Hz, 3H); 13C{1H} NMR (100 
MHz, CDCl3) δ 172.2, 170.5, 155.4, 141.9, 136.5, 134.9, 130.2, 130.1, 129.5, 129.1, 128.3, 126.6, 125.9, 
123.8, 122.1, 79.7, 56.4, 55.8, 51.8, 41.4, 38.0, 37.2, 28.1, 16.1. HRMS (m/z): calcd. for C28H35BrN2O5Na 
581.1627; found, 581.1605. IR (thin film): 3318, 1686, 1650, 701 cm-1. 
Methyl (5S,6S,E)-6-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-6-cyclopropyl-5-
methylhex-3-enoate ((S)-10f). Obtained as a pale yellow gum (639 mg, 95% yield, two steps) after 
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deprotection of compound 9 to compound S3 (General Procedure B), which was immediately coupled with 
Boc-L-phenylalanine (General Procedure C). [α]23D -36 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.36-
7.23 (m, 5H), 6.33 (br d, J = 9.4 Hz, 1H), 5.50-5.39 (m, 2H), 5.29 (td, J = 7.2, 15.0 Hz, 1H), 4.39 (br q, J = 
7.0 Hz, 1H), 3.74 (s, 3H), 3.39-3.29 (m, 1H), 3.08 (br d, J = 5.5 Hz, 2H), 3.04 (d, J = 7.0 Hz, 2H), 2.28 (br 
q, J = 6.3 Hz, 1H), 1.47 (s, 9H), 1.04 (br d, J = 6.3 Hz, 3H), 0.76 (dtd, J = 5.1, 8.6, 13.3 Hz, 1H), 0.56 (t, J 
= 8.2 Hz, 1H), 0.43-0.26 (m, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 172.2, 170.4, 155.2, 136.7, 135.9, 
129.2, 128.3, 126.6, 122.7, 121.2, 79.6, 56.7, 56.1, 51.6, 41.6, 38.3, 37.4, 32.7, 28.1, 16.6, 12.2, 4.7, 1.4; 
HRMS (m/z): calcd. for C25H36N2O5Na, 467.2522; found, 467.2532. IR (thin film): 3309, 1740, 1686, 1651, 
699 cm-1. 
Methyl (5S,6S,E)-6-((R)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-6-cyclopropyl-5-
methylhex-3-enoate ((R)-10f). Obtained as a pale yellow solid (522 mg, 70% yield, two steps) after 
deprotection of compound 9 to compound S3 (General Procedure B), which was immediately coupled with 
Boc-D-phenylalanine (General Procedure C). mp 121-124 °C; [α]23D +9 (c 1.0, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.25-7.15 (m, 5H), 6.11 (br d, J = 7.4 Hz, 1H), 5.46-5.38 (m, 2H), 5.32 (td, J = 6.6, 15.2 
Hz, 1H), 4.33 (br q, J = 7.0 Hz, 1H), 3.65 (s, 3H), 3.23-3.14 (m, 1H), 3.05-3.00 (m, 1H), 2.99-2.95 (m, 3H), 
2.45-2.30 (m, 1H), 1.40-1.34 (m, 9H), 1.01 (br d, J = 7.0 Hz, 3H), 0.69-0.55 (m, 1H), 0.46 (br s, 1H), 0.32-
0.12 (m, 2H), 0.06 (br s, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 172.5, 170.8, 170.2, 155.3, 136.8, 135.8, 
135.5, 129.3, 129.2, 128.4, 128.3, 126.5, 122.9, 79.5, 57.0, 56.96, 55.9, 51.6, 41.6, 38.2, 37.4, 37.3, 36.8, 
28.1, 16.5, 16.2, 11.9, 4.8, 1.6; HRMS (m/z): calcd. for C25H36N2O5Na, 467.2522; found, 467.2521. IR (thin 
film): 3338, 1737, 1684, 1649, 753, 697 cm-1. 
tert-Butyl (S)-2-(((1R,2S,E)-6-methoxy-2-methyl-6-oxo-1-phenylhex-3-en-1-yl)carbamoyl)pyrrolidine-1-
carboxylate ((S)-10g). Obtained as a yellow oil (268 mg, 73% yield, two steps) after deprotection of 
compound 7 to compound S1 (General Procedure B), which was immediately coupled with Boc-L-proline 
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(General Procedure C). 1H NMR in CDCl3 indicated an approximate 9:1 ratio of Boc rotamers with 
significant broadening and peak overlap; major signals are reported. [α]23D +26 (c 7.75, CHCl3); 1H NMR 
(400 MHz, CDCl3) Major rotamer: δ 7.30-7.15 (m, 5H), 5.60-5.47 (m, 1H), 5.40-5.25 (m, 1H), 4.89 (dd, J 
= 5.9, 9.0 Hz, 1H), 4.40-4.30 (br. m, 1H), 3.66 (s, 3H), 3.54-3.22 (br m, 3H), 3.0 (br. s, 2H), 2.65-2.51 (m, 
1H), 1.90-1.75 (br. m, 3H), 1.47 (br. s, 9H), 0.98 (br. s, 3H); Minor rotamer: δ 7.30-7.15 (m, 5H), 5.60-5.47 
(m 1H), 5.40-5.25 (m, 1H), 4.84 (dd, J = 9.4, 7.4 Hz, 1H), 4.30-4.20 (br. m, 1H), 3.64 (s, 3H), 3.54-3.22 
(br m, 1H), 2.90-2.75 (m, 2H), 2.65-2.51 (m, 1H), 2.45-2.32 (br. m, 3H), 1.47 (br. s, 9H), 0.98 (br. s, 3H); 
13C{1H} NMR (100 MHz, CDCl3, mixture of rotamers, all peaks reported) δ 172.0, 171.8, 156.0, 154.6, 
140.3, 135.5, 127.9, 127.1, 126.7, 122.9, 121.7, 80.2, 60.2, 59.5, 56.9, 46.9, 42.0, 37.6, 32.7, 28.8, 28.2, 
28.0, 27.2, 24.4, 23.5, 17.0, 15.8, 14.0; HRMS (m/z): [M+Na]+ calcd. for C24H34N2O5Na, 453.2365; found, 
453.2370; IR (thin film): 3309, 1738, 1659, 753, 701 cm-1. 
tert-Butyl (R)-2-(((1R,2S,E)-6-methoxy-2-methyl-6-oxo-1-phenylhex-3-en-1-yl)carbamoyl)pyrrolidine-1-
carboxylate ((R)-10g). Obtained as an orange oil (372 mg, 67% yield, two steps) after deprotection of 
compound 15 to compound S1 (General Procedure B), which was immediately coupled with Boc-D-proline 
(General Procedure C). 1H NMR in DMSO-d6 indicated an approximately 1.7:1 mixture of Boc rotamers 
with significant broadening and peak overlap; signals for the major identified rotamer are reported. [α]23D 
+99 (c 1.75, CHCl3); 1H NMR (400 MHz, DMSO-d6) δ 8.06 (d, J = 9.0 Hz, 1H), 7.30-7.15 (m, 5H), 5.45-
5.21 (m, 2H), 4.75-4.57 (m, 1H), 4.20-4.10 (m, 1H), 3.53 (s, 3H), 3.40-3.30 (m, 1H) 3.30-3.22 (m, 1H), 
3.00-2.85 (m, 2H), 2.70-2.55 (m, 1H), 2.17-2.07 (m, 1H), 1.80-1.60 (m, 3H), 1.25 (s, 9H), 1.00-0.90 (m, 
3H). 13C{1H} NMR (100 MHz, DMSO-d6, mixture of rotamers, all peaks reported) δ 171.5, 171.4, 153.7, 
153.4, 142.1, 141.7, 136.2, 127.8, 127.2, 126.6, 122.2, 78.6, 78.3, 59.7, 59.4, 57.1, 56.5, 51.4, 46.7, 46.6, 
41.5, 41.1, 37.1, 31.1, 29.6, 28.1, 28.0, 24.0, 23.0, 16.9, 16.2; HRMS (m/z): [M+Na]+ calcd. for 
C24H34N2O5Na, 453.2365; found, 453.2376; IR (thin film): 3312, 1739, 1696, cm-1. 
30 
 
General Procedure D: Boc deprotection. Compound 10 was dissolved in CH2Cl2 to give a 0.2 M solution. 
The solution was transferred to a microwave vessel. SCX resin (1.5 equiv, 0.54 mmol/g) was added in one 
portion and the reaction was subjected to microwave irradiation (300W maximum wattage, 100 °C 
maximum temperature, 250 psi maximum pressure) for 10 minutes. The vessel was allowed to cool to room 
temperature before opening, and the resin was isolated by filtration, rinsing with three portions of 
dichloromethane. The resin was return to the cleaned microwave vessel and a solution of 3:1 CH2Cl2:Et3N 
was added. The vessel was subjected to microwave irradiation (300W maximum wattage, 60 °C maximum 
temperature, 250 psi maximum pressure) for three minutes to release the deprotected amine. The vessel 
was then cooled to room temperature and the resin was filtered from the solution, rinsing with three portions 
of dichloromethane. The mother liquor was condensed to give the crude deprotected product 1 which was 
carried on to the cyclization step without further purification. 
General Procedure E: DBU-mediated cyclization. The crude amine 1a-g from the Boc deprotection step 
was dissolved in acetonitrile to give an 0.1M solution. DBU (2.0 equiv) was added and the reaction was 
heated to 90 °C for three hours. Upon completion as indicated by LC/MS, the reaction mixture was directly 
applied to a short column of silica (1 cm diameter, maximum length 3 cm) wetted with 5% acetone in 
hexanes. The product was eluted with 50 mL portions of the following gradient: 5%, 10%, 20%, 30%, 40%, 
50%, 60%, 80% acetone in hexanes. 
General Procedure F: Sodium methoxide-mediated cyclization. The crude amine 1a-g from the Boc 
deprotection step (1.0 equiv) was dissolved in anhydrous DMF at room temperature (0.1 M concentration). 
A solution of sodium methoxide in methanol (25% w/w, 2.0 equiv) was added in one portion and the 
reaction was stirred at room temperature for 30 minutes. When LC/MS indicated reaction completion, the 
solution was diluted with 50 volume equivalents of ethyl acetate, washed with 6 portions of water (2 mL 
water per 1 mL original reaction volume), and washed once with brine. The organic fraction was dried over 
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sodium sulfate and condensed to give a crude residue. The residue was applied to a short column of silica 
(1 cm diameter, maximum length 3 cm) wetted with 5% acetone in hexanes. The product was eluted with 
50 mL portions of the following gradient: 5%, 10%, 20%, 30%, 40%, 50%, 60%, 80% acetone in hexanes. 
(4S,7R,8S,9aS)-4-Benzyl-8-methyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione ((S,S)-
3a). Obtained as a white solid from compound (S)-10a after deprotection (General Procedure D) to afford 
(S)-1a followed by cyclization using General Procedure E (64 mg, 81% yield, 6:1 d.r., 1H NMR chemical 
shifts for minor diastereomer appear to correlate to compound (R,R)-3a). Also obtained as major product 
when compound (S)-1a was subjected to cyclization using General Procedure F (56 mg, 72% yield, 13:1 
d.r.). mp = 172-175 °C; [α]23D -56 (c 1.05, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.35-7.28 (m, 4H), 7.27-
7.21 (m, 4H), 7.13-7.09 (m, 2H), 5.78 (br. d, J = 3.5 Hz, 1H), 5.18 (d, J = 8.2 Hz, 1H), 4.42 (ddd, J = 3.5, 
5.3, 9.0 Hz, 1H), 4.28 (dddd, J = 5.0, 6.3, 10.0, 10.5 Hz, 1H), 3.33 (dd, J = 5.3, 14.5 Hz, 1H), 3.04 (dd, J 
= 5.1, 17.6 Hz, 1H), 2.81 (dd, J = 10.5, 17.5 Hz, 1H), 2.84 (dd, J = 9.0, 14.5 Hz, 1H), 2.50 (qdd, J = 6.6, 
8.0, 13.4 Hz, 1H), 2.29 (td, J = 6.3, 12.5 Hz, 1H), 1.55 (ddd, J = 10.0, 12.5, 13.4 Hz, 1H), 0.67 (d, J = 6.6 
Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 171.1, 169.0, 138.2, 136.3, 129.3, 128.8, 128.2, 126.9, 66.2, 
54.8, 52.9, 42.0, 40.8, 36.5, 36.1, 14.8; HRMS (m/z): [M+H]+ calcd. for C22H25N2O2, 349.1916; found, 
349.1906. IR (thin film): 3260, 1667, 1639, 742, 696 cm-1. 
(4R,7R,8S,9aR)-4-Benzyl-8-methyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione 
((R,R)-3a). Obtained as a clear oil from compound (R)-10a after deprotection (General Procedure D) to 
afford (R)-1a followed by cyclization using General Procedure F (45 mg, 98% yield, 7.5:1 d.r., 1H NMR 
chemical shifts for minor diastereomer appear to correlate to compound (S,S)-3a). [α]23D +12.5 (c 0.08, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.37-7.20 (m, 8H), 7.08 (d, J = 7.0 Hz, 2H), 5.60 (br. s., 1H), 5.18 
(d, J = 8.2 Hz, 1H), 4.68-4.61 (m, 1H), 4.57 (ddd, J = 2.7, 4.5, 10.0 Hz, 1H), 3.30 (dd, J = 4.5, 15.0 Hz, 
1H), 2.82 (dd, J = 10.0, 15.0 Hz, 1H), 2.77-2.64 (m, 3H), 2.12 (dt, J = 8.4, 13.0 Hz, 1H), 1.74 (dd, J = 6.1, 
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13.1 Hz, 1H), 0.67 (d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 170.8, 167.3, 138.4, 135.9, 
129.2, 129.1, 128.3, 127.4, 127.3, 126.5, 65.4, 54.5, 52.5, 42.7, 37.4, 36.3, 34.4, 14.8; HRMS (m/z): [M+H]+ 
calcd. for C22H25N2O2, 349.1916; found, 349.1915; IR (thin film) 3205, 1656, 796, 747, 702 cm-1. 
(4S,7R,8S,9aS)-4-Isobutyl-8-methyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione 
((S,S)-3b). Obtained as a white solid from compound (S)-10b after deprotection (General Procedure D) to 
afford (S)-1b followed by cyclization using General Procedure E (81 mg, 81% yield, 17:1 d.r., 1H NMR 
chemical shifts for minor diastereomer appear to correlate to compound (R,R)-3b). Also obtained as major 
product when compound (S)-1b was subjected to cyclization using General Procedure F (46 mg, 65% yield, 
3:1 d.r.). mp = 160-163 °C; [α]23D +520 (c 0.94, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.36-7.28 (m, 2H), 
7.26-7.21 (m, 1H), 7.11 (d, J = 7.1 Hz, 2H), 5.64 (br. d, J = 4.7 Hz, 1H), 5.18 (d, J = 8.2 Hz, 1H), 4.32 
(dddd, J = 5.9, 6.3, 9.8, 10.0 Hz, 1H), 4.19 (ddd, J = 4.7, 5.1, 8.6 Hz, 1H), 3.17 (dd, J = 5.9, 17.2 Hz, 1H), 
2.91 (dd, J = 9.8, 17.2 Hz, 1H), 2.53 (dqdd, J = 6.3, 7.0, 8.2, 12.9 Hz, 1H), 2.34 (td, J = 6.3, 12.5 Hz, 1H), 
1.84 (ddd, J = 5.8, 8.6, 14.3 Hz, 1H), 1.73 (dqqd, J = 5.8, 6.3, 6.6, 8.6 Hz, 1H), 1.61 (ddd, J = 10.0, 12.5, 
12.9 Hz, 1H), 1.47 (ddd, J = 4.7, 8.6, 14.3 Hz, 1H), 0.97 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 6.3 Hz, 3H), 0.69 
(d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 171.1, 169.8, 138.3, 128.3, 127.2, 126.9, 65.9, 
53.1, 51.3, 42.0, 41.3, 39.0, 36.2, 24.4, 23.0, 21.9, 14.9; HRMS (m/z): [M+H]+ calcd. for C19H27N2O2, 
315.2073; found, 315.2076. IR (thin film) 3209, 1658, 805, 744, 701 cm-1. 
(4R,7R,8S,9aR)-4-Isobutyl-8-methyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione 
((R,R)-3b). Obtained as a pale yellow oil from compound (R)-10b after deprotection (General Procedure 
D) to afford (R)-1b followed by cyclization using General Procedure F (21 mg, 94% yield, 7:1 d.r., 1H 
NMR chemical shifts for minor diastereomer appear to correlate to compound (S,S)-3b). [α]23D +182 (c 
0.69, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.35-7.28 (m, J = 7.8 Hz, 3H), 7.05 (d, J = 7.4 Hz, 2H), 5.58 
(s, 1H), 5.14 (d, J = 7.8 Hz, 1H), 4.68 (ddd, J = 3.9, 8.3, 12.1 Hz, 1H), 4.34 (ddd, J = 3.0, 6.3, 7.7 Hz, 1H), 
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2.85 (dd, J = 3.9, 18.0 Hz, 1H), 2.74 (dd, J = 12.1, 18.0 Hz, 1H), 2.80-2.65 (m, 1H), 2.11 (dt, J = 8.3, 13.0 
Hz, 1H), 1.85 (ddd, J = 6.3, 7.9, 14.0 Hz, 1H), 1.74-1.63 (m, 1H), 1.65-1.55 (m, 1H), 1.41 (ddd, J = 6.4, 
7.7, 14.0 Hz, 1H), 0.94 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H), 0.66 (d, J = 6.6 Hz, 3H); 13C{1H} 
NMR (100 MHz, CDCl3) δ 171.0, 167.8, 138.6, 128.3, 127.3, 126.5, 65.2, 52.7, 51.4, 42.6, 39.1, 37.4, 34.4, 
24.4, 22.7, 22.0, 14.8; HRMS (m/z): [M+H]+ calcd. for C19H27N2O2, 315.2073; found, 315.2058. IR (thin 
film) cm-1. 
(4S,7R,8S,9aS)-4-Isopropyl-8-methyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione 
((S,S)-3c). Obtained as an amorphous pale yellow solid from compound (S)-10c after deprotection (General 
Procedure D) to afford (S)-1c followed by cyclization using General Procedure E (50 mg, 72% yield of a 
single diastereomer after chromatography). [α]23D +131 (c 1.3, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.30-
7.23 (m, 2H), 7.21-7.14 (m, 1H), 7.09-7.02 (m, 2H), 5.89 (br d, J = 5.9 Hz, 1H), 5.12 (d, J = 8.2 Hz, 1H), 
4.24 (tdd, J = 6.3, 9.0, 10.8 Hz, 1H), 3.80 (dd, J = 5.9, 7.0 Hz, 1H), 3.12 (dd, J = 6.3, 17.2 Hz, 1H), 2.86 
(dd, J = 9.0, 17.2 Hz, 1H), 2.46 (sptd, J = 6.6, 7.0 Hz, 1H), 2.27 (dd, J = 6.3, 12.8 Hz, 1H), 2.23 (qdd, J = 
7.0, 8.2, 12.8 Hz, 1H), 1.57 (dt, J = 10.8, 12.8 Hz, 1H), 0.99 (t, J = 6.6 Hz, 1H), 1.06-0.92 (m, 5H), 0.62 
(d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 171.7, 169.3, 138.6, 128.3, 127.1, 126.9, 65.8, 
58.9, 53.2, 41.9, 41.3, 36.1, 28.1, 20.4, 18.0, 14.9; HRMS (m/z): [M+H]+ calcd. for C18H25N2O2, 301.1916; 
found, 301.1912. IR (thin film) 2961, 1659, 748 cm-1. 
(4R,7R,8S,9aR)-4-Isopropyl-8-methyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione 
((R,R)-3c). Obtained as a clear oil from compound (R)-10c after deprotection (General Procedure D) to  
(R)-1c followed by cyclization using General Procedure F) (16 mg, 91% yield of a single diastereomer after 
chromatography). [α]23D -285 (c 0.19, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.35-7.22 (m, 3H), 7.09-7.02 
(m, 2H), 5.78 (br s, 1H), 5.15 (d, J = 7.8 Hz, 1H), 4.67 (ddd, J = 4.3, 8.1, 12.2 Hz, 1H), 4.03 (dd, J = 3.9, 
7.0 Hz, 1H), 2.86 (dd, J = 4.3, 18.4 Hz, 1H), 2.73 (dd, J = 12.2, 18.4 Hz, 1H), 2.70 (dqdd, J = 6.0, 6.6, 7.8, 
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13.1 Hz, 1H), 2.27-2.17 (m, 1H), 2.09 (dt, J = 8.2, 13.1 Hz, 1H), 1.73 (dd, J = 6.0, 12.7 Hz, 1H), 1.06 (d, J 
= 6.6 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H), 0.67 (d, J = 6.6 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 
171.2, 167.7, 138.6, 128.3, 127.2, 65.0, 58.7, 52.7, 42.6, 37.5, 34.4, 27.8, 20.2, 17.7, 14.9; HRMS (m/z): 
[M+H]+ calcd. for C18H25N2O2, 301.1916; found, 301.1911. IR (thin film) 1653, 744 cm-1. 
(4S,7R,8S,9aS)-4,8-Dimethyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione ((S,S)-3d). 
Obtained as a clear oil from compound (S)-10d after deprotection (General Procedure D) to (S)-1d followed 
by cyclization using General Procedure E (39 mg, 58% yield, 12:1 d.r., 1H NMR chemical shifts of minor 
diastereomer do not appear to match (R,R)-3d). [α]23D +311 (c 0.16, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 7.33-7.28 (m, 2H), 7.26-7.21 (m, 1H), 7.11 (d, J = 7.4 Hz, 2H), 6.01 (br d, J = 4.0 Hz, 1H), 5.19 (d, J = 
8.2 Hz, 1H), 4.34 (dq, J = 4.0, 6.6 Hz, 1H), 4.30 (dddd, J = 5.3, 6.3, 10.0, 10.6 Hz, 1H), 3.13 (dd, J = 5.3, 
17.8 Hz, 1H), 2.89 (dd, J = 10.6, 17.8 Hz, 1H), 2.51 (dqdd, J = 6.3, 6.6, 8.2, 12.8 Hz, 1H), 2.34 (td, J = 6.3, 
12.8 Hz, 1H), 1.57 (dt, J = 10.0, 12.8 Hz, 1H), 1.38 (d, J = 6.6 Hz, 3H), 0.69 (d, J = 6.6 Hz, 3H); 13C{1H} 
NMR (100 MHz, CDCl3) δ 171.0, 170.0, 135.2, 128.3, 127.2, 127.0, 66.0, 52.9, 48.8, 42.1, 41.0, 36.3, 16.0, 
14.9; HRMS (m/z): [M+H]+ calcd. for C16H21N2O2, 273.1603; found, 273.1602. IR (thin film) 3220, 1653, 
735 cm-1. 
(4R,7R,8S,9aR)-4,8-Dimethyl-7-phenylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione ((R,R)-3d). 
Obtained as a clear oil from compound (R)-10d after deprotection (General Procedure D) to afford (R)-1d 
followed by cyclization using General Procedure F (38 mg, 56% yield, 9:1 d.r., 1H NMR chemical shifts of 
minor diastereomer appear to match (S,S)-3d). [α]23D +27 (c 0.87, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
7.33-7.22 (m, 3H), 7.04 (d, J = 7.4 Hz, 2H), 6.18 (br. s., 1H), 5.12 (d, J = 8.2 Hz, 1H), 4.61 (ddd, J = 4.3, 
8.2, 11.9 Hz, 1H), 4.45 (dq, J = 2.7, 6.6 Hz, 1H), 2.80-2.65 (m, 3H), 2.09 (dt, J = 8.2, 13.1 Hz, 1H), 1.71 
(dd, J = 6.3, 13.1 Hz, 1H), 1.32 (d, J = 6.6 Hz, 3H), 0.64 (d, J = 6.6 Hz, 3H); 13C{1H} NMR (100 MHz, 
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CDCl3) δ 171.2, 168.0, 138.6, 128.3, 127.3, 126.5, 65.4, 52.5, 49.2, 42.6, 37.4, 34.4, 16.3, 14.8; HRMS 
(m/z): [M+H]+ calcd. for C16H21N2O2, 273.1603; found, 273.1602. IR (thin film) 1654, 749, 701 cm-1. 
(4S,7R,8S,9aS)-4-Benzyl-7-(3-bromophenyl)-8-methylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-
dione ((S,S)-3e). Obtained as a white foam from compound (S)-10e after deprotection (General Procedure 
D) to (S)-1e followed by cyclization using General Procedure E. 1H NMR analysis of the crude isolate 
suggested an initial 4.3:1 d.r.; the chemical shifts of the observed minor diastereomer did not match (R,R)-
2e and are presumed to be another, undetermined diastereomer. After chromatography, (S,S)-3e was 
isolated as a single diastereomer in 74% yield (69 mg). [α]23D -1.9 (c 3.3, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.39 (dd, J = 1.2, 7.4 Hz, 1H), 7.35-7.30 (m, 2H), 7.29-7.17 (m, 5H), 7.03 (d, J = 7.8 Hz, 1H), 
5.74 (d, J = 4.3 Hz, 1H), 5.12 (d, J = 8.2 Hz, 1H), 4.41 (ddd, J = 4.3, 5.3, 9.0 Hz, 1H), 4.27 (ddt, J = 5.1, 
6.2, 10.2 Hz, 1H), 3.33 (dd, J = 5.3, 14.7 Hz, 1H), 3.05 (dd, J = 5.1, 17.6 Hz, 1H), 2.85 (dd, J = 9.0, 14.7 
Hz, 1H), 2.77 (dd, J = 10.2, 17.6 Hz, 1H), 2.52 (dqdd, J = 6.2, 7.0, 8.2, 12.7 Hz, 1H), 2.31 (td, J = 6.2, 12.7 
Hz, 1H), 1.55 (dt, J = 10.2, 12.7 Hz, 1H), 0.69 (d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 
171.1, 169.2, 140.9, 136.3, 136.0, 130.5, 130.4, 130.2, 129.9, 129.5, 129.3, 129.0, 128.9, 127.4, 127.2, 
125.3, 122.5, 67.2, 65.7, 58.2, 55.2, 55.1, 53.1, 41.9, 40.9, 40.7, 39.3, 38.6, 36.6, 36.1, 35.1, 14.9; HRMS 
(m/z): [M+H]+ calcd. for C22H24BrN2O2, 427.1021; found, 427.1013. IR (thin film): 3211, 1653, 749, 700 
cm-1. 
(4R,7R,8S,9aR)-4-Benzyl-7-(3-bromophenyl)-8-methylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-
dione ((R,R)-3e).  Obtained as a clear oil from compound (R)-10e after deprotection (General Procedure D) 
to (R)-1e followed by cyclization using General Procedure E. 1H NMR analysis of the crude isolate 
suggested an initial 3.2:1 d.r.; the chemical shifts of the observed minor diastereomer do not match (S,S)-
3e and it is presumed to be another, unspecified diastereomer. After chromatography, (R,R)-3e was isolated 
as a single diastereomer in 68% yield (56 mg). [α]23D +5.5 (c 2.15, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
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7.45 (d, J = 7.0 Hz, 1H), 7.41-7.35 (m, 2H), 7.34-7.28 (m, 3H), 7.26-7.20 (m, 2H), 7.07 (d, J = 7.8 Hz, 1H), 
5.95 (d, J = 2.3 Hz, 1H), 5.19 (d, J = 8.2 Hz, 1 H), 4.68 (br ddd, J = 6.0, 8.2, 9.8 Hz, 1 H), 4.62 (ddd, J = 
2.8, 5.1, 9.4 Hz, 1 H), 3.35 (dd, J = 5.1, 14.9 Hz, 1 H), 2.88 (dd, J = 9.4, 14.9 Hz, 1 H), 2.79 (qdd, J = 6.6, 
8.2, 13.0 Hz, 1 H), 2.80 (d, J = 18.4 Hz, 1 H), 2.75 (dd, J = 9.8, 18.4 Hz, 1 H), 2.11 (dt, J = 8.4, 13.0 Hz, 1 
H), 1.78 (dd, J = 6.0, 13.0 Hz, 1 H), 0.73 (d, J = 6.6 Hz, 3 H); 13C{1H} NMR (400 MHz, CDCl3) δ 170.8, 
167.5, 141.1, 136.1, 130.5, 129.8, 129.2, 129.1, 129.0, 127.2, 125.4, 122.6, 64.7, 54.5, 52.5, 42.4, 37.4, 
36.0, 34.3, 14.8; HRMS (m/z): [M+H]+ calcd. for C22H24BrN2O2, 427.1021; found, 427.1014. IR (thin film): 
3210, 1654, 750, 701 cm-1. 
(4S,7R,8S,9aS)-4-Benzyl-7-cyclopropyl-8-methylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione 
((S,S)-3f). Obtained as a white solid from compound (S)-10f after deprotection (General Procedure D) to 
(S)-1f followed by cyclization using General Procedure E (31 mg, 68% yield as a single diastereomer after 
chromatography, 1H NMR analysis of the crude isolate suggested a single diastereomer formed under the 
reaction conditions). Mp = 232-236 °C; [α]23D -22 (c 0.8, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.35-7.30 
(m, 2H), 7.28-7.22 (m, 3H), 5.75 (br s, 1H), 4.43 (ddd, J = 2.7, 4.9, 9.5 Hz, 1H), 4.17 (dddd, J = 3.5, 7.2, 
9.0, 12.2 Hz, 1H), 3.52 (dd, J = 7.0, 10.2 Hz, 1H), 3.38 (dd, J = 4.9, 14.8 Hz, 1H), 2.87 (dd, J = 3.5, 18.3 
Hz, 1H), 2.84 (dd, J = 9.5, 14.8 Hz, 1H), 2.54 (dd, J = 12.2, 18.3 Hz, 1H), 2.38 (ddd, J = 6.8, 7.4, 12.5 Hz, 
1H), 2.25 (dddq, J = 6.6, 6.8, 7.0, 12.7 Hz, 1H), 1.52 (dt, J = 9.0, 12.7 Hz, 1H), 1.15 (d, J = 6.6 Hz, 3H), 
0.81-0.73 (m, 1H), 0.70-0.60 (m, 1H), 0.58-0.44 (m, 2H), 0.30-0.22 (m, 1H); 13C{1H}NMR (100 MHz, 
CDCl3) δ 170.8, 168.5, 136.3, 129.2, 129.0, 127.2, 66.1, 54.1, 51.8, 43.8, 40.2, 36.5, 14.5, 14.4, 11.9, 3.9, 
2.4; HRMS (m/z): [M+H]+ calcd. for C19H25N2O2, 313.1916, found 313.1915. IR (thin film): 3318, 1740, 
1686, 1650 cm-1. 
(4R,7R,8S,9aR)-4-Benzyl-7-cyclopropyl-8-methylhexahydro-1H-pyrrolo[1,2-d][1,4]diazepine-2,5-dione 
((R,R)-3f). Obtained as a clear oil from compound (R)-10f after deprotection (General Procedure D) to 
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afford (R)-1f followed by cyclization using General Procedure E (53 mg, 66% yield as a single 
diastereomer, 1H NMR analysis of the crude isolate suggested an initial 4:1 d.r., with the chemical shifts of 
the minor isomer matching (S,S)-3f. [α]23D -24 (c 1.2, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.32-7.18 (m, 
5H), 5.61 (br s, 1H), 4.42-4.40 (m, 1H), 4.40 (ddd, J = 2.8, 5.3, 9.4 Hz, 1H), 4.30 (ddd, J = 4.3, 8.2, 11.6 
Hz, 1H), 3.55 (dd, J = 7.4, 9.8 Hz, 1H), 3.31 (dd, J = 5.3, 14.7 Hz, 1H), 2.81 (dd, J = 9.4, 14.7 Hz, 1H), 
2.58 (dd, J = 4.3, 18.0 Hz, 1H), 2.50 (dd, J = 11.6, 18.0 Hz, 1H), 2.40 (dqdd, J = 6.0, 6.6, 7.4, 12.9 Hz, 1H), 
2.06 (dt, J = 8.2, 12.9 Hz, 1H), 1.62 (dd, J = 5.5, 12.9 Hz, 1H), 1.11 (d, J = 6.6 Hz, 3H), 0.85-0.76 (m, 1H), 
0.62-0.53 (m, 1H), 0.47-0.37 (m, 2H), 0.18-0.11 (m, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 171.3, 168.3, 
136.6, 129.6, 129.3, 127.5, 66.1, 55.0, 51.8, 43.3, 385.7, 36.9, 34.6, 14.9, 11.9, 3.8, 3.3; HRMS (m/z): 
[M+H]+ calcd. for C19H25N2O2, 313.1916; found, 313.1904. IR (thin film): 3206, 1651, 753, 701 cm-1. 
(2S,3R,5aS,11aS)-2-Methyl-3-phenyloctahydro-5H-dipyrrolo[1,2-a:1',2'-d][1,4]diazepine-5,10(1H)-
dione ((5aS,11aS)-3g). Obtained as the major diastereomeric product (amorphous white solid) from 
compound (S)-10g after deprotection (General Procedure D) to afford (S)-1g followed by cyclization using 
General Procedure E (52 mg, 75% yield, 14:1 d.r., 1H NMR chemical shifts of minor diastereomer 
correlated with product (5aR,11aR)-3g). In addition, the major diastereomer obtained after treating (S)-1g 
under General Procedure F (31 mg, 61% yield, 14:1:1 d.r., 1H NMR chemical shifts of minor diastereomers 
correlated with products (5aR,11aR)-3g and (5aR,11aS)-3g), and when treating compound (5aR,11aS)-3g 
under General Procedure F. The diastereomeric ratio was further enriched by repeated chromatography for 
2D NMR characterization purposes. [α]23D -31 (c 3.4, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.34-7.27 (m, 
2H), 7.24 (d, J = 6.6 Hz, 1H), 7.10 (d, J = 7.0 Hz, 2H), 5.17 (d, J = 8.2 Hz, 1H), 4.52 (dd, J = 5.7, 7.6 Hz, 
1H), 4.30 (dddd, J = 4.7, 6.3, 9.8, 11.5 Hz, 1H), 3.64 (td, J = 7.0, 11.7 Hz, 1H), 3.56 (td, J = 6.6, 11.7 Hz, 
1H), 3.13 (dd, J = 4.7, 18.0 Hz, 1H), 2.93 (dd, J = 11.5, 18.0 Hz, 1H), 2.63 (dtd, J = 5.7, 6.4, 12.8 Hz, 1H), 
2.50 (dqdd, J = 6.3, 6.9, 8.2, 12.5 Hz, 1H), 2.33 (td, J = 6.3, 12.5 Hz, 1H), 2.04 (tdd, J = 7.0, 7.6, 12.8 Hz, 
1H), 1.85 (tdd, J = 6.4, 7.0, 12.9 Hz, 1H), 1.77 (dtd, J = 6.4, 7.0, 12.9 Hz, 1H), 1.53 (dt, J = 9.8, 12.5 Hz, 
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1H), 0.68 (d, J = 6.9 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 168.9, 167.3, 138.1, 128.3, 127.2, 127.0, 
125.4, 57.2, 53.0, 48.0, 43.0, 40.6, 36.3, 28.2, 22.3, 14.9; HRMS (m/z): [M+H]+ calcd. for C18H23N2O2, 
299.1760; found, 299.1758. IR (thin film): 1657, 1617, 1439, 747, 701 cm-1. 
(2S,3R,5aR,11aR)-2-Methyl-3-phenyloctahydro-5H-dipyrrolo[1,2-a:1',2'-d][1,4]diazepine-5,10(1H)-
dione ((5aR,11aR)-3g). Obtained as the major diastereomeric product (orange oil) from compound (R)-10g 
after deprotection (General Procedure D) to (R)-1g followed by cyclization using General Procedure F (61 
mg, 59% yield, 87:21:1 d.r., 1H NMR chemical shifts of minor diastereomers correlated with products 
(5aS,11aS)-3g and (5aR,11aS)-3g, respectively). The diastereomeric ratio was further enriched by repeated 
chromatography for 2D NMR characterization purposes. [α]23D +248 (c 0.5, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.35-7.23 (m, 3H), 7.06 (d, J = 8.2 Hz, 2H), 5.10 (d, J = 7.8 Hz, 1H), 4.64 (ddd, J = 4.0, 8.0, 12.5 
Hz, 1H), 4.61 (br dd, J = 6.6, 7.0 Hz, 1H), 3.67 (dd, J = 7.0, 12.0 Hz, 1H), 3.60 (dd, J = 6.6, 12.0 Hz, 1H), 
2.85 (dd, J = 4.0, 18.5 Hz, 1H), 2.77 (br dd, J = 12.5, 18.5 Hz, 1H), 2.72 (dqdd, J = 6.3, 7.0, 7.8, 13.0 Hz, 
2H), 2.58 (dddd, J = 6.3, 6.6, 7.0, 13.5 Hz, 1H), 2.12 (dt, J = 8.0, 13.0 Hz, 1H), 2.02 (br qd, J = 6.6, 13.5 
Hz, 1H), 1.90 (tdd, J = 6.6, 7.0, 13.0 Hz, 1H), 1.80 (dtd, J = 6.3, 6.6, 13.0 Hz, 1H), 1.74 (dd, J = 6.3, 13.0 
Hz, 1H), 0.66 (d, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 167.8, 167.1, 138.6, 128.3, 127.3, 
126.6, 65.4, 57.8, 52.9, 48.4, 43.2, 37.3, 34.5, 28.3, 22.4, 14.8; HRMS (m/z): [M+H]+ calcd. for C18H23N2O2, 
299.1760; found, 299.1761. IR (thin film): 1660, 1619, 750, 702 cm-1. 
(2S,3R,5aR,11aS)-2-Methyl-3-phenyloctahydro-5H-dipyrrolo[1,2-a:1',2'-d][1,4]diazepine-5,10(1H)-
dione ((5aR,11aS)-3g). Obtained as the major diastereomeric product (orange oil) from compound (R)-10g 
after deprotection (General Procedure D) to (R)-1g followed by cyclization using General Procedure E (52 
mg, 50% yield, 4:1:1 d.r., 1H NMR chemical shifts of minor diastereomers correlated with products 
(5aS,11aS)-3g and (5aR,11aR)-3g). The diastereomeric ratio was further enriched by repeated 
chromatography for 2D NMR characterization purposes. [α]23D +27 (c 0.4, CHCl3); 1H NMR (400 MHz, 
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CDCl3) δ 7.37-7.28 (m, 2H), 7.27-7.21 (m, 1H), 7.14-7.08 (m, 2H), 5.06 (d, J = 9.0 Hz, 1H), 4.42 (t, J = 
7.2 Hz, 1H), 4.06 (ddd, J = 5.1, 11.1, 11.3 Hz, 1H), 3.79 (td, J = 6.6, 12.0 Hz, 1H), 3.43 (td, J = 7.0, 12.0 
Hz, 1H), 3.14 (dd, J = 11.1, 14.5 Hz, 1H), 2.88 (d, J = 14.5 Hz, 1H), 2.55 (d, J = 14.1 Hz, 1H), 2.44 (td, J 
= 7.0, 13.7 Hz, 1H), 2.21 (qd, J = 6.6, 14.1 Hz, 1H), 2.04 (td, J = 5.3, 12.0 Hz, 1H), 1.88-1.65 (m, 3H), 0.58 
(d, J = 6.6 Hz, 3H); 13C{1H} (100 MHz, CDCl3) δ 171.8, 166.4, 139.6, 128.2, 127.1, 126.4, 67.3, 61.6, 57.4, 
47.6, 40.8, 39.6, 35.0, 30.9, 30.0, 22.9, 14.8; HRMS (m/z): [M+H]+ calcd. for C18H23N2O2, 299.1760; found, 
299.1755. IR (thin film): 1639, 750, 702 cm-1. 
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